• Inicio
  • Resultados de la búsqueda
  • 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.

3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.

Biochemical pharmacology (2013-09-03)
Jian-Ming Lü, Qizhi Yao, Changyi Chen
RESUMEN

Hyperuricemia, excess of uric acid in the blood, is a clinical problem that causes gout and is also considered a risk factor for cardiovascular disease. The enzyme xanthine oxidase (XO) produces uric acid during the purine metabolism; therefore, discovering novel XO inhibitors is an important strategy to develop an effective therapy for hyperuricemia and gout. We found that 3,4-dihydroxy-5-nitrobenzaldehyde (DHNB), a derivative of the natural substance protocatechuic aldehyde, potently inhibited XO activity with an IC₅₀ value of 3 μM. DHNB inhibited XO activity in a time-dependent manner, which was similar to that of allopurinol, a clinical XO inhibitory drug. DHNB displayed potent mixed-type inhibition of the activity of XO, and showed an additive effect with allopurinol at the low concentration. Structure-activity relationship studies of DHNB indicated that the aldehyde moiety, the catechol moiety, and nitration at C-5 were required for XO inhibition. DHNB interacted with the molybdenum center of XO and was slowly converted to its carboxylic acid at a rate of 10⁻¹⁰ mol/L/s. In addition, DHNB directly scavenged free radical DPPH and ROS, including ONOO⁻ and HOCl. DHNB effectively reduced serum uric acid levels in allantoxanamide-induced hyperuricemic mice. Furthermore, mice orally given a large dose (500 mg/kg) of DHNB did not show any side effects, while 42% of allopurinol (500 mg/kg)-treated mice died and their offspring lost their fur. Thus, DHNB could be an outstanding candidate for a novel XO inhibitory drug that has potent activity and low toxicity, as well as antioxidant activity and a distinct chemical structure from allopurinol.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Xanthine Oxidase from bovine milk, Grade I, ammonium sulfate suspension, ≥0.4 units/mg protein
Sigma-Aldrich
3,4-Dihydroxybenzaldehyde, 97%
Sigma-Aldrich
Allopurinol, xanthine oxidase inhibitor
Sigma-Aldrich
Xanthine Oxidase from bovine milk, lyophilized powder, 0.4-1.0 units/mg protein
Sigma-Aldrich
Xanthine Oxidase microbial, lyophilized powder, ≥7 units/mg solid
Sigma-Aldrich
Xanthine Oxidase from bovine milk, Grade III, ammonium sulfate suspension, ≥0.8 units/mg protein
Sigma-Aldrich
Molybdenum, powder, <150 μm, 99.9% trace metals basis
Sigma-Aldrich
Xanthine Oxidase from bovine milk, Grade IV, ammonium sulfate suspension, ≥0.1 units/mg protein
Sigma-Aldrich
Molybdenum, powder, 1-5 μm, ≥99.9% trace metals basis
Sigma-Aldrich
Molybdenum, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Molybdenum, powder, <150 μm, 99.99% trace metals basis
Sigma-Aldrich
Molybdenum, foil, thickness 0.025 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Molybdenum, nanopowder, <100 nm particle size (TEM), 99.8% trace metals basis
Sigma-Aldrich
3,4-Dihydroxybenzaldehyde, purum, ≥97.0% (HPLC)
Allopurinol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Molybdenum, wire, diam. 1.0 mm, 99.95% trace metals basis
Sigma-Aldrich
Molybdenum, foil, thickness 1.0 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Molybdenum, foil, thickness 0.05 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Molybdenum, powder, 10 μm, ≥99.95% trace metals basis